MorphoSys Announces Clinical Milestone in Cancer Antibody Program with Bayer HealthCare Pharmaceuticals
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces Clinical Milestone in Cancer Antibody Program with Bayer
HealthCare Pharmaceuticals
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that
Bayer HealthCare Pharmaceuticals has reached the next milestone by initiating a
Phase 1 clinical trial with the HuCAL-derived antibody-drug conjugate BAY
94-9343 in the therapeutic area of oncology. This achievement marks the second
clinical milestone within MorphoSys's alliance with Bayer HealthCare.
"Today's news underlines once again the substantial clinical output our partners
have generated based on our HuCAL platform. Based on the number of clinical
candidates in development we believe HuCAL to be the most successful antibody
library technology in the pharmaceutical industry," commented Dr. Marlies
Sproll, Chief Scientific Officer of MorphoSys AG.
The current program BAY 94-9343 is directed against the target molecule
mesothelin. Mesothelin is highly expressed on mesotheliomas and on ovarian and
pancreatic tumors. BAY 94-9343 is the second fully human HuCAL-based antibody-
drug conjugate (ADC) to enter clinical trials. ADCs comprise antibodies linked
to cytotoxic drugs, and combine the targeting properties of an antibody with the
cell-destroying effect of a conjugated drug. In preclinical testing, BAY
94-9343 demonstrated potent, targeted anticancer activity against mesothelin-
expressing tumors.
MorphoSys projected that in 2011 between one and three partnered programs could
enter clinical trials. Today's news represents the second HuCAL-derived antibody
to enter clinical development this year. In total, MorphoSys's clinical pipeline
now comprises twelve partnered programs in Phase 1 and five in Phase 2
development as well as the Company's proprietary programs MOR103, which is in a
Phase 1b/2a trial for rheumatoid arthritis, MOR208, which is in a Phase 1/2a
trial for chronic lymphocytic leukemia and MOR202, which is in a Phase 1/2a
trial for multiple myeloma.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys; arYla(TM) is a trademark of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release (PDF):
http://hugin.info/130295/R/1546288/474398.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1546288]
Unternehmensinformation / Kurzprofil:
Datum: 14.09.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 64416
Anzahl Zeichen: 6348
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 245 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Clinical Milestone in Cancer Antibody Program with Bayer HealthCare Pharmaceuticals"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
